Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.

Véronique HofmanJonathan JucoLingkang HuangVeronique HofmanShirin Khambata-FordPaul Hofman

Published in: Cancer cytopathology (2018)

ASL48 and BenchMark Ultra 22C3 antibody concentrate-based LDTs have been validated for PD-L1 testing in cytology samples, and they will support reliable, high-quality PD-L1 testing across regions globally. Cancer Cytopathol 2018;126:264-74. © 2018 American Cancer Society.

Keyphrases

papillary thyroid
end stage renal disease
squamous cell
high grade
fine needle aspiration
newly diagnosed
ejection fraction
poor prognosis
peritoneal dialysis
prognostic factors
high resolution
squamous cell carcinoma
childhood cancer
patient reported outcomes